<DOC>
	<DOCNO>NCT00589602</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Removing T cell donor cell transplant may stop happen . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help destroy remain cancer cell ( graft-versus-tumor effect ) . PURPOSE : This phase II trial study T-cell depletion donor stem cell transplant follow delayed T cell infusion treat patient hematologic cancer disease .</brief_summary>
	<brief_title>T-Cell Depletion , Donor HSCT , T-Cell Infusions Treating Patients With Hematologic Cancer Other Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine T-cell depletion peripheral blood progenitor cell ( PBPC ) graft follow delayed add-backs defined dos donor lymphocytes decrease rate graft-versus-host disease complication match unrelated donor ( MUD ) allogeneic PBPC transplantation patient hematologic cancer disease . - Determine whether target T-cell dosage PBPC graft achieve patient positive CD34+ selection use Baxter Inc. Isolex 300i v. 2.5 . - Determine effect T-cell depletion rate engraftment patient . - Develop MUD allogeneic transplantation regimen decrease overall treatment-related mortality patient . OUTLINE : This non-randomized study . - Myeloablative preparative regimen : Patients receive cyclophosphamide IV daily day -5 -4 follow total body irradiation twice daily day -3 , -2 , -1 . Patients also receive tacrolimus day -1 administer continuous IV infusion 24 hour . - Peripheral blood progenitor cell graft transplantation : Patients receive T-cell deplete , peripheral blood progenitor cell ( PBPC ) IV infusion day 0 . Beginning 1 day completion PBPC infusion , patient receive filgrastim ( G-CSF ) subcutaneously daily blood count recover . - Post transplantation T cell add-backs : Patients receive define dos donor T cell IV infusion day 45 100 , absence active graft-versus-host disease ( GVHD ) require steroids* . NOTE : *A T cell add-back may give presence GVHD , investigator considers risk relapse overwhelming viral infection outweigh risk exacerbate GVHD . Patients follow periodically relapse survival .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis follow hematologic cancer disease : Acute myelogenous leukemia Relapsed refractory disease poorrisk cytogenetics Acute lymphoblastic leukemia Relapsed refractory disease poorrisk cytogenetics Chronic myelogenous leukemia Persistent disease least 6 month treatment imatinib mesylate ( Gleevec ) Myelodysplasia , meet 1 follow criterion : FrenchAmericanBritish Classification refractory anemia excess blast ( RAEB ) RAEB transformation International Prognostic Scoring System score &gt; 2 Lymphoid malignancy , include nonHodgkin lymphoma , Hodgkin disease , chronic lymphocytic leukemia , prolymphocytic leukemia Relapsed refractory disease least 1 prior therapy Myelofibrosis Transfusion dependent ( RBC 's , platelet , ) Paroxysmal nocturnal hemoglobinuria ( transfusion dependent ) Myeloproliferative disorder Eosinophilic leukemia Severe aplastic anemia Corrected reticulocyte count &lt; 1 % Platelet count &lt; 30,000/mm³ ( untransfused ) Bone marrow biopsy &lt; 15 % cellularity Plasma cell leukemia No essential thrombocytopenia polycythemia vera No match related donor available Must 8/8 7/8 serologic HLA match unrelated donor available PATIENT CHARACTERISTICS : Cardiac ejection fraction ≥ 45 % ( &lt; 45 % , cardiac consult require ) Not pregnant nursing Negative pregnancy test FEV_1 DLCO ≥ 45 % predict Creatinine &lt; 2.0 mg/dL Bilirubin &lt; 2.0 mg/dL HIV negative PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior allogeneic bone marrow transplantation No concurrent administration steroid Tcell addbacks INCLUSION CRITERIA : Patient actual weight must great 1.5x ideal body weight Cardiac ejection fraction &gt; 45 % . If less 45 % , Cardiac consult obtain . A suitably match unrelated donor least 7 8 HLA serologic match . Patient pregnant . FEV 1 DLCO &gt; 45 % predict pulmonary function test . Serum creatinine &lt; 2.0 mg/dl , serum bilirubin &lt; 2.0 mg/dl . Patient donor HIV negative . Diagnosis one follow disease Acute myelogenous leukemia Relapsed disease , Refractory disease , With poorrisk cytogenetics Acute lymphoblastic leukemia Relapsed disease , Refractory disease , With poorrisk cytogenetics Chronic myelogenous leukemia Persistent disease least 6 month treatment Imatinib Mesylate ( Gleevec ) Myelodysplasia FAB Classification RAEB RAEBT Or IPSS score &gt; 2 Lymphoid malignancy , include nonHodgkin 's lymphoma , Hodgkin 's disease , chronic lymphocytic leukemia prolymphocytic leukemia Relapsed refractory disease least 1 prior therapy Myelofibrosis Transfusion dependence ( RBC 's , platelet , ) Paroxysmal Nocturnal Hemoglobinuria ( PNH ) Transfusion dependent Myeloproliferative Disorder Eosinophilic Leukemia Severe aplastic anemia ( &lt; 1 % correct reticulocyte count , &lt; 30,000 untransfused platelet count , bone marrow biopsy &lt; 15 % cellularity ) Plasma cell leukemia Patients ET PV candidate unless disease transform end stage myelofibrosis acute leukemia , eligibility criterion myelofibrosis acute leukemia would apply . Patient must sign write informed consent . EXCLUSION CRITERIA : Inability give inform consent Absence mention medical condition Availability matchedrelated donor History prior allogeneic BMT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Adult luekemias</keyword>
	<keyword>lymphoma</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>plasma cell disorder</keyword>
</DOC>